A mathematical model

1st in the UK for research impact, with 100% research rated world-leading (REF2021), the School of Mathematical Sciences is at the forefront of mathematical research

Research Groups

  • Pure Mathematics

    We have strong research groups across a wide spectrum of pure mathematics, including algebra, analysis, combinatorics, geometry, geometric rigidity theory, mathematical physics and probability.

  • Statistics

    Research in statistics at Lancaster focuses on the interface of methodology and application. We believe that strong interaction with research users is imperative for developing new statistical ideas that are of practical importance.

What we do

  • Research Centres and Networks

    We have two Research Centres and participate in a number of formal research networks. We also have strategic links, locally, nationally and internationally.

  • Statistical Collaborations

    Researchers are keen to collaborate on interesting problems. Our statistical research already has strong links with computing, management science, medical research, environmental science and criminology.

  • Conferences

    Lancaster plays host to many leading conferences in Mathematical Sciences research.

Mathematical Sciences seminars

Sorry, we looked but there are no events currently scheduled in this area.

More Events

Flooding in York in 2015

Research Impact

Lancaster has a strong tradition of collaborative research with end-users and a track record of research that has led to impact.

Examples of impact from our research include:

  • Use of extreme value research to guide design of coastal flood defences throughout the UK
  • Crucial input into the High Court's investigation into the sinking of the M.V. Derbyshire, and the consequent introduction of new design standards for bulk carriers
  • Statistical genetics research that highlighted poultry as the primary source of Campylobacteriosis infections in humans in New Zealand, resulting in a new code of practice for the poultry industry and a halving of human cases
  • Use of robust adaptive designs across a number of clinical trials leading to more cost-efficient trials, and early-stopping of trials of drugs that are clearly not effective